Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer

Cancer

Volumn 119, Issue 20, 2013, Pages 3604-3609

  Jin, Zhe ^a,b,c   Zhao, Zhenfu ^a   Cheng, Yulan ^d   Dong, Ming ^a   Zhang, Xiaojing ^a   Wang, Liang ^a   Fan, Xinmin ^a   Feng, Xianling ^a   Mori, Yuriko ^d   Meltzer, Stephen J ^d  

^a Shenzhen University School of Medicine   (China)

^b Shenzhen Key Laboratory of Micromolecule Innovative Drugs   (China)

^c PEKING UNIVERSITY   (China)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; endoglin; esophageal adenocarcinoma; esophageal squamous cell carcinoma; hypermethylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ENDOGLIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DNA METHYLATION; EARLY DIAGNOSIS; ENDOGLIN GENE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC;

BIOMARKER; ENDOGLIN; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HYPERMETHYLATION;

ADENOCARCINOMA; AGED; ANTIGENS, CD; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84885189346     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28276     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
2. Zhang XM, Guo MZ,. The value of epigenetic markers in esophageal cancer. Front Med China. 2010; 4: 378-384.
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
4. Gougos A, Letarte M,. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem. 1990; 265: 8361-8364.
5. Cheifetz S, Bellon T, Cales C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992; 267: 19027-19030.
6. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995; 1: 1623-1634. (Pubitemid 26030991)
7. McAllister KA, Baldwin MA, Thukkani AK, et al. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum Mol Genet. 1995; 4: 1983-1985.
8. Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer. 1999; 81: 568-572. (Pubitemid 29203054)
9. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999; 59: 856-861. (Pubitemid 29086739)
10. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A,. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate. 2002; 51: 268-275. (Pubitemid 34556377)
11. Shovlin CL, Hughes JM, Scott J, Seidman CE, Seidman JG,. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. 1997; 61: 68-79. (Pubitemid 27323325)
12. Fonsatti E, Del Vecchio L, Altomonte M, et al. Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol. 2001; 188: 1-7. (Pubitemid 32476491)
13. Shariat SF, Karam JA, Walz J, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 2008; 14: 3785-3791.
14. Dammann R, Strunnikova M, Schagdarsurengin U, et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer. 2005; 41: 1223-1236. (Pubitemid 40725582)
15. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006; 131: 797-808. (Pubitemid 44307065)
16. Henry LA, Johnson DA, Sarrio D, et al. Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene. 2011; 30: 1046-1058.
17. Wong VC, Chan PL, Bernabeu C, et al. Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer. 2008; 123: 2816-2823.
18. Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene. 2005; 24: 4138-4148. (Pubitemid 40897058)
19. Jin Z, Mori Y, Yang J, et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007; 26: 6332-6340. (Pubitemid 47462110)
20. Jin Z, Olaru A, Yang J, et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res. 2007; 13: 6293-6300. (Pubitemid 350075017)
21. Leung WK, Yu J, Ng EK, et al. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer. 2001; 91: 2294-2301. (Pubitemid 32552815)
22. Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene. 2003; 22: 2352-2360. (Pubitemid 36566790)
23. Holst CR, Nuovo GJ, Esteller M, et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 2003; 63: 1596-1601. (Pubitemid 36373649)
24. Nuovo GJ, Nakagawa H, Sotamaa K, Chapelle Ade L,. Hypermethylation of the MLH1 promoter with concomitant absence of transcript and protein occurs in small patches of crypt cells in unaffected mucosa from sporadic colorectal carcinoma. Diagn Mol Pathol. 2006; 15: 17-23.
25. Ishii T, Murakami J, Notohara K, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut. 2007; 56: 13-19. (Pubitemid 46044883)
26. Jin Z, Hamilton JP, Yang J, et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev. 2008; 17: 111-117. (Pubitemid 351196280)
27. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL,. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs. 2005; 16: 301-308. (Pubitemid 40283945)
28. Momparler RL,. Epigenetic therapy of cancer with 5-aza-2′- deoxycytidine (decitabine). Semin Oncol. 2005; 32: 443-451. (Pubitemid 41396420)